Literature DB >> 15804961

Detection of interleukin 10 in cerebrospinal fluid of patients with subacute sclerosing panencephalitis.

A S Mistchenko1, M C Fornari, M Viegas, P R Barrero, R A Diez.   

Abstract

Subacute sclerosing panencephalitis (SSPE) is a neurodegenerative disorder due to persistent measles virus infection, with high level of measles-specific antibodies in cerebrospinal fluid (CSF). To analyze whether such response arises from a TH2-biased response, the authors determined TH1 (interferon [IFN]-gamma) and TH2 (interleukin [IL]-4 and IL-10) cytokines in CSF, taken at diagnosis, of eight SSPE patients (median age, 57.5 month, range 42 to 76 months). All patients presented IL-10 (median 29.3 pg/ml, range 4.3 to 162 pg/ml), but not IL-4 (<10 pg/ml); only one case showed IFN-gamma (162 pg/ml). These results are consistent with a TH2 bias or with a local, anti-inflammatory or neuroprotective mechanism involving IL-10.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15804961     DOI: 10.1080/13550280590901769

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  18 in total

1.  Differential regulation of interleukin (IL)-4, IL-5, and IL-10 during measles in Zambian children.

Authors:  William J Moss; Judith J Ryon; Mwaka Monze; Diane E Griffin
Journal:  J Infect Dis       Date:  2002-09-13       Impact factor: 5.226

Review 2.  Subacute sclerosing panencephalitis.

Authors:  R K Garg
Journal:  Postgrad Med J       Date:  2002-02       Impact factor: 2.401

3.  Measles virus-specific T helper 1/T helper 2-cytokine production in subacute sclerosing panencephalitis.

Authors:  T Hara; S Yamashita; H Aiba; K Nihei; N Koide; R A Good; K Takeshita
Journal:  J Neurovirol       Date:  2000-04       Impact factor: 2.643

Review 4.  Neuroprogressive disease of post-infectious origin: a review of a resurging subacute sclerosing panencephalitis (SSPE).

Authors:  P R Dyken
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2001

5.  Production of interleukin-10 in the cerebrospinal fluid in aseptic meningitis of children.

Authors:  A Ishiguro; Y Suzuki; Y Inaba; A Komiyama; H P Koeffler; T Shimbo
Journal:  Pediatr Res       Date:  1996-10       Impact factor: 3.756

6.  Interleukin-10 modulates neuronal threshold of vulnerability to ischaemic damage.

Authors:  M Grilli; I Barbieri; H Basudev; R Brusa; C Casati; G Lozza; E Ongini
Journal:  Eur J Neurosci       Date:  2000-07       Impact factor: 3.386

Review 7.  Interleukin-10 in the brain.

Authors:  K Strle; J H Zhou; W H Shen; S R Broussard; R W Johnson; G G Freund; R Dantzer; K W Kelley
Journal:  Crit Rev Immunol       Date:  2001       Impact factor: 2.214

8.  Immune-mediated protection from measles virus-induced central nervous system disease is noncytolytic and gamma interferon dependent.

Authors:  Catherine E Patterson; Diane M P Lawrence; Lisa A Echols; Glenn F Rall
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  LPS/IFN-gamma cytotoxicity in oligodendroglial cells: role of nitric oxide and protection by the anti-inflammatory cytokine IL-10.

Authors:  E Molina-Holgado; J M Vela; A Arévalo-Martín; C Guaza
Journal:  Eur J Neurosci       Date:  2001-02       Impact factor: 3.386

10.  Wild-type measles virus in brain tissue of children with subacute sclerosing panencephalitis, Argentina.

Authors:  Paola Roxana Barrero; Jorge Grippo; Mariana Viegas; Alicia Susana Mistchenko
Journal:  Emerg Infect Dis       Date:  2003-10       Impact factor: 6.883

View more
  2 in total

Review 1.  Blue moon neurovirology: the merits of studying rare CNS diseases of viral origin.

Authors:  Lauren A O'Donnell; Glenn F Rall
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-24       Impact factor: 7.285

2.  Immune alterations in subacute sclerosing panencephalitis reflect an incompetent response to eliminate the measles virus.

Authors:  Sibel P Yentür; Veysi Demirbilek; Candan Gurses; Safa Baris; Umit Kuru; Semih Ayta; Zuhal Yapici; Suzan Adin-Cinar; Serap Uysal; Gulden Celik Yilmaz; Emel Onal; Ozlem Cokar; Güher Saruhan-Direskeneli
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.